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Background: Therapeutic plasma exchange (TPE) is an important treatment modality for various diseases, but its
use can be restricted by allergic reactions (AR). The aim of our study was to elucidate the frequency of and risk
factors for AR at initial TPE using fresh frozen plasma (FFP).
Methods: Presences of AR were extracted from the medical records of consecutive patients receiving TPE from
2002 to 2012. The following data at initial TPE were retrieved: age, gender, history of allergy, steroid use, timing of
steroid use, mean steroid dose, immunosuppressant use, indication for TPE, and laboratory data.
Results: Eighty-eight patients (median age 57 years) underwent TPE, and 28% had an episode of AR. Younger age
(odds ratio (OR), 1.04 (95% CI, 1.01–1.08)) and indications other than hepatic insufficiency (OR, 17.8 (95% CI,
1.95–429.4)) were associated with higher incidence of AR.
Conclusions: Close observation for AR may be warranted at initial TPE for these conditions.
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Therapeutic plasma exchange (TPE) is an important
treatment option for various diseases, including thrombotic
microangiopathy, antineutrophil cytoplasmic antibody-
associated vasculitis, rheumatic diseases (such as systemic
lupus erythematosus and scleroderma), and hepatic fail-
ure. Therapeutic plasma exchange is essential in ABO-
incompatible kidney transplantation, which has gradually
become a common therapy in living-related kidney trans-
plantation in Japan [1]. In most instances, the therapeutic
goal of TPE is the removal of harmful proteins or anti-
bodies. The use of albumin may be favored as a replace-
ment fluid when possible because of its low cost and low
frequency of adverse events. However, replacement using* Correspondence: mika0104hisapy@yahoo.co.jp
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Though TPE is not without adverse events. Bramlage
et al. [2] reported that up to 25.6% of TPE procedures
were associated with adverse events including catheter-
related problems, infections, and allergic reactions (AR).
One review [3] noted that AR due to TPE occurred in
3–12% of cases and were more frequent after TPE using
FFP than using serum albumin. However, the predictors
of AR after TPE using FFP are not well known. The aim
of this study was to determine the frequency of AR after
initial TPE using FFP and to document possible risk fac-
tors involved in the incidence of AR in TPE.Methods
Study population and definition of allergic reaction
Medical records of consecutive patients who received
TPE using FFP at St. Marianna University School of
Medicine hospital from March 2002 to February 2012le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Patient characteristics and results of univariate logistic
regression analysis of association between AR
Whole cohort (n = 88) P value
Age (years) 57 (36–70) 0.01**
Gender, men 52 (59%) 0.71
Body weight (kg) 54 (48–63) 0.12*
Use of steroid before TPE 72 (77%)
Start of steroid use No steroid on day of TPE Reference
The day of TPE 5 (6%) 0.15*
1–7 days before TPE 24 (27%) 0.29
>7 days before TPE 39 (44%) 0.40
Prednisolone-equivalent dose





History of allergy 26 (30%) 0.47





Hepatic failure 18 (20%) 0.01**
Others 57 (65%) 0.11*
Amount of FFP (units/kg) 0.69 (0.60–0.75) 0.14*
White blood cell count (/μl) 8850 (5100–13,100) 0.04**
Hemoglobin (g/dl) 8.8 (7.0–10.7) 0.80
Platelet count (103/μl) 108 (54.5–217.8) 0.59
Serum creatinine (mg/dl) 2.77 (0.69–6.25) 0.02**
Serum albumin (g/dl) 3.0 (2.6–3.5) 0.33
Serum C-reactive protein (mg/dl) 1.12 (0.16–4.52) 0.39
Data presented as median (interquartile range) or n (%)
FFP fresh frozen plasma, TPE therapeutic plasma exchange
*P < 0.2, ** < 0.05 the correlation in univariate logistic regression analysis.
Categories that were associated in P < 0.2 were adapted to multivariate analysis
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time of initial TPE were retrieved: age, gender, history of
allergy, steroid use, timing of steroid use, mean steroid
dose (as equivalent of prednisolone), immunosuppressant
use, indication for TPE, and laboratory data (white blood
cell count, hemoglobin, platelet count, creatinine, albumin,
and C-reactive protein).
Episodes of AR were extracted from the medical records
of clinically diagnosed AR by the attending physician such
as rashes, pruritus, transient decrease of blood pressure,
tachycardia, and respiratory symptoms (i.e., sudden onset
of dyspnea, wheezing). Nonspecific symptoms such as
nausea and vomiting were interpreted as AR when other
symptoms coexisted or treated as AR. The severity of AR
was classified as mild, moderate, or severe by the corre-
sponding medical action taken to treat AR in reference to
previous literature [2]. Briefly, mild AR included reactions
of transient nature with little or no clinical significance
that did not cause any procedural delays. Moderate AR
included complications that required medical interven-
tion but were not life-threatening. Severe AR included
life-threatening events that required termination of the
procedure.
The study protocol was reviewed by the Ethics Com-
mittee of St. Marianna University School of Medicine
(the committee’s reference number: No. 2452, 12 June
2013). Because of the anonymous and retrospective na-
ture of the study, the Ethics Committee waived the
need for informed consent. The study was conducted in
accordance with the ethical standards of the Helsinki
Declaration as revised in Fortaleza, 2013.
Therapeutic plasma exchange procedure
Therapeutic plasma exchange was carried out using an
OctoNova1 system (Diamed, Cologne, Germany) with an
OP05W (L) 1-filter (Asahi, Tokyo, Japan). The replacement
fluid was FFP. The blood flow rate ranged from 50 to
200 ml/min, and the plasma removal and replacement
rates ranged from 25 to 35 ml/min. The exchanged
plasma volume was 35 to 40 ml/kg body weight per TPE
session. Nafamostat mesilate (30 mg/h) was administered
by infusion as an anticoagulant.
Statistical analysis
Univariate logistic regression analysis was conducted to
identify risk factors for AR at initial TPE. Variables with
P < 0.2 were identified by stepwise backward elimination
and further investigated as independent risk factors using
multivariable logistic regression. Data are presented as
median and interquartile range (25th to 75th percentile)
or percentage. All analyses were performed using JMP
10 (SAS Institute Inc., Cary, NC, USA). All tests are
presented with two-sided P values, and P < 0.05 was con-
sidered significant.Results
Patient characteristics
Demographics and clinical characteristics are described
in Table 1. During the study period, a total of 88 patients
(52 men) received TPE. The median age was 57 years
(interquartile range, 36–70 years). The distribution of
patient age seemed to be common in 20s and from 50s to
70s (Fig. 1). Indications for TPE were ABO-incompatible
kidney transplantation (n = 13, 15%), hepatic failure (n =
18, 20%), and other diseases (n = 57, 65%). Other diseases
for indication included rheumatic disease, thrombotic
microangiopathy, myasthenia gravis crisis, hyperviscosity
syndrome, ANCA-associated vasculitis/nephritis, anti-
glomerular basement membrane nephritis, interstitial
pneumonia, crescentic glomerulonephritis due to pur-
pura nephritis, systemic lupus erythematosus, alveolar
hemorrhage, and cryoglobulinemia. Twenty-six patients
(30%) had past history of allergy. Seventy-two patients
Fig. 1 Graph showing the distribution of patient age. Ages are
represented in decades
Table 3 Results of multivariable logistic regression analysis for
allergic reaction to initial TPE
Odds ratio 95% CI P value






Hepatic failure 0.06 0.002–0.51 0.03
Others 0.73 0.17–3.10 0.66
CI confidence interval, TPE therapeutic plasma exchange
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prednisolone-equivalent dose of 20 mg (interquartile
range, 0.63–60 mg), and 26 patients (28%) used
immunosuppressants.Incidence and predicting factors of allergic reaction
Twenty-five out of 88 patients (28%) experienced AR.
The severity of AR was evaluated as mild in 8 patients
(32% of whole AR patients), moderate in 11 (44%), and
severe in 6 (24%; Table 2).
The factors related with AR by univariate logistic re-
gression analysis (P < 0.2) were age, body weight, start of
steroid use (from the day of TPE), use of immunosup-
pressant, history of blood transfusion, indication for TPE
(hepatic failure, others), amount of FFP used, white
blood cell count, and serum creatinine. Multivariable lo-
gistic regression analysis revealed that the risk of AR in
hepatic failure was significantly low and that younger
age was independently associated with a higher occur-
rence of AR (Table 3).Following TPE procedures after AR in initial TPE
The incidence and context of second TPE within those
with AR is described in Table 4. Within the 25 presenting
with AR, 11 were withdrawn from the following TPE.Table 2 Occurrence and severity of allergic reaction to initial
therapeutic plasma exchange
Number % of total cohort
(n = 88)
% of patients with allergic




Severity of allergic reaction
Mild 8 9.1 32
Moderate 11 12.5 44
Severe 6 6.8 24Discussion
In this single-center study, 28% of 88 patients experi-
enced AR after initial TPE using FFP as a replacement
fluid. We focused on AR at initial TPE because this is
likely to have the greatest impact on the decision to con-
tinue or discontinue TPE and select subsequent treat-
ment. As far as we know, there are no studies on AR
that have focused on initial TPE using FFP. Apheresis
using albumin has been reported to present rash or
pruritus in 0.2 to 0.3% of cases [4]. The incidence of AR
observed in this study was unexpectedly high compared
to others that reported rates of 3~12% [3] which in-
cluded TPE with albumin-saline exchange. The high in-
cidence of AR compared to other studies may be caused
because our study was limited to events on the initial
session and those with AR on initial PE tend to with-
draw the following sessions which will raise the rates of
AR per session. In such perspective, the rate of AR can-
not simply be compared with other studies including all
PE sessions. The AR seen in this study may reflect reac-
tions not only to FFP but also to other components of
TPE, such as anticoagulation drugs [5] and materials
used in the extracorporeal circuit [6]. Our analysis can-
not differentiate the cause of AR. It is noteworthy, how-
ever, that FFP transfusion causes AR in less than 3% of
patients [7], suggesting that FFP may not be the primary
cause. Although severe AR were less common than mild
or moderate AR, 24% of all AR were graded as severe,
which cannot be disregarded.
Younger age and disorders other than hepatic insuffi-
ciency as indications for TPE were suggestive of higher
risk for AR. The reason for the association between youn-
ger age and AR is not clear; however, it may reflect the fact
that the response against foreign antigens decrease alongTable 4 Incidence and context of second TPE within those with
AR at initial TPE
FFP Albumin Withdrawn Total
Mild 5 0 3 8
Moderate 8 0 3 11
Severe 1 0 5 6
Total 14 0 11 25
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single-center study showed that acute allergic reactions
after blood transfusion in children were more frequent
than in adults [10]. Warm et al. reported that the asso-
ciation between allergic sensitization and rhinitis was
strongest among the youngest age group and the preva-
lence of allergic sensitization among patients with
asthma decreased by increasing age of asthma onset
[11]. As shown in the figure, although the median age
of our cohort was 57 years old, many elderly were also
involved which perhaps may be one of the reasons why
we experienced quite a few incidents of AR.
Patients with acute and chronic liver dysfunction show
a similar degree of cellular immune depression as patients
with severe sepsis, with features of systemic inflammation
and progression to functional immunoparesis [12, 13].
Since immediate-type allergy is induced by network of not
only the humoral immunity but also the cellular immunity
[14], these features of immunoparesis might explain the
low frequency of AR in patients who received TPE due to
hepatic insufficiency.
This result suggest that close observation would be re-
quired when conducting TPE using FFP especially in the
younger patients and those with conditions other than
hepatic insufficiency. Prevention of AR is another im-
portant point that needs to be considered. Our result
did not show association of steroid use before TPE and
allergic reactions. The use of steroid for the prevention
of AR is somewhat controversial. A systematic review
concluded that data supporting the use of steroids as
premedication in patients with a history of AR are lacking
[15]. On the other hand, guidelines for pharmacological
prophylaxis for contrast media-related AR recommend
the use of steroids for more than 12 h before a procedure
[16]. This guideline was based on the improved prophylac-
tic effect obtained by steroids administered at least 6 h in
advance [17], as well as the observation that the reduction
of histamine in sedimented leukocytes reaches a max-
imum at 8 h after steroid administration [16]. Although
our result did not show significant prophylactic effect
with steroid use, further investigations are needed to
verify whether premedication with steroids might be
beneficial when administered more than 1 day prior to
TPE. Whether immunosuppressants are effective on
prevention of AR may need more data including type of
drug, serum concentration, and period of therapy. Con-
cerning the use of antihistamine drug, we could not in-
vestigate the actual conditions in detail. The lesson
learned from our study was that AR in initial TPE using
FFP is quite frequent. As incidence of AR is reported to
be lower with albumin exchange [3, 4], those indicated
should be recommended for albumin exchange. Further-
more, those with non-hepatic indication and young are at
higher risk of AR when initiating FFP replacement, evenwhen on steroids or immunosuppressants, rendering fur-
ther attention for AR in this population.
Compared to previous reports [2, 4] and reviews [3],
we included patients with a wider variety of indications,
including hepatic failure, desensitization before ABO-
incompatible kidney transplantation, various rheumatic
diseases (or autoimmune diseases including systemic
lupus erythematosus, vasculitis), and thrombotic throm-
bocytopenic purpura. We categorized these diseases into
three groups for comparison analysis according to major
mechanism and/or purpose. The purpose of TPE in hep-
atic failure is the removal of toxic metabolites and the
replacement of mainly coagulant factors; desensitization
before ABO-incompatible kidney transplantation is the
removal of antibodies not harmful to autoantigen and
the replacement of mainly coagulant factors; and others,
primarily rheumatic diseases, are the removal of anti-
bodies harmful to autoantigen and replenishing plasma
proteins.
The limitations of this study are its small sample size
and retrospective, single-center design. The wide variety
of disorders diverse in pathophysiology and each small
in number were allocated into three groups for analysis.
The indication for FFP use was hepatic dysfunction and
TMA which is acknowledged in many facilities as rela-
tive indications. However, indication for other diseases
were left to the judgment of the attending physician
which may potentiate selection bias. The definition of
AR was challenging which should be stated as another
limitation in this study. Precise differentiation between
other pathophysiological disorders are difficult especially
when analyzed retrospectively, and therefore, many ad-
verse events may be over-diagnosed as allergic reactions.
In addition, our analysis cannot differentiate the cause of
AR, i.e., cannot identify whether AR was due to FFP or
to other allergens present in TPE (such as anticoagu-
lants) or the extracorporeal circuit. Further research
should also investigate the role of the complex patho-
physiology of the indicative diseases, which were more
varied in this population compared to previous studies.Conclusions
We found that AR at initial TPE using FFP occurred fre-
quently (28% of all cases). Moreover, greater than 24% of
AR were classified as severe, requiring termination of
TPE and treatment. Younger patients and those with in-
dications other than hepatic failure were at relatively
higher risk for AR and warrant close observation during
initial TPE.Abbreviations
AR: Allergic reactions; FFP: Fresh frozen plasma; OR: Odds ratio;
TPE: Therapeutic plasma exchange
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